Marburg Multiple Sclerosis Variant: Complete Remission with Very Early Administration of Mitoxantrone-A Case Report.

Case report Marburg’s variant Mitoxantrone Multiple sclerosis

Journal

Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 30 09 2021
accepted: 23 11 2021
pubmed: 4 12 2021
medline: 4 12 2021
entrez: 3 12 2021
Statut: ppublish

Résumé

Marburg variant is a severe and fulminant pseudotumor form of multiple sclerosis (MS) with high morbidity and mortality rates. Because of its scarcity, it remains incompletely characterized and physicians' experiences will influence the treatment. We report the inflammatory explosive case of a 31-year-old woman presenting with rapid neurological degradation of histology proven Marburg's disease, successfully treated with early administration of Mitoxantrone (MITX). To our knowledge, it is the first case describing complete remission after MITX in a biopsy-proven condition.

Identifiants

pubmed: 34859363
doi: 10.1007/s40120-021-00308-6
pii: 10.1007/s40120-021-00308-6
pmc: PMC8638644
doi:

Types de publication

Journal Article

Langues

eng

Pagination

507-513

Informations de copyright

© 2021. The Author(s).

Références

Marburg O. Die sogennante akute multiple Sklerose. Mitt Ges Inn Med Kinderheilk Wien. 1905;4:200.
Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G. Marburg’s variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun. 1999;1(1):48–51. https://doi.org/10.1006/mcbr.1999.0111 (PMID: 10329477).
doi: 10.1006/mcbr.1999.0111 pubmed: 10329477
Elenein RG, Sharer LR, Cook SD, Pachner AR, Michaels J, Hillen ME. A second case of Marburg’s variant of multiple sclerosis with vasculitis and extensive demyelination. Mult Scler. 2011;17(12):1531–8. https://doi.org/10.1177/1352458511414042 (PMID: 21816761).
doi: 10.1177/1352458511414042 pubmed: 21816761
Suzuki M, Kawasaki H, Masaki K, Suzuki SO, Terada T, Tsuchida T, et al. An autopsy case of the marburg variant of multiple sclerosis (acute multiple sclerosis). Intern Med. 2013;52(16):2532.
doi: 10.2169/internalmedicine.52.0425
Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 Suppl 6):S15–8. https://doi.org/10.1212/wnl.63.12_suppl_6.s15 (PMID: 15623664).
doi: 10.1212/wnl.63.12_suppl_6.s15 pubmed: 15623664
Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM). J Neurol. 2020;267(10):2799802.
doi: 10.1007/s00415-020-09951-9
Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord. 2017;14:729.
doi: 10.1016/j.msard.2017.04.003
Nunes J, Radbruch H, Walz R, Lin K, Stenzel W, Prokop S, et al. The most fulminant course of the Marburg variant of multiple sclerosis—autopsy findings. Mult Scler J. 2015;21(4):4857.
doi: 10.1177/1352458514537366
Duan H, Luo Y, Hao H, Feng L, Zhang Y, Lu D, et al. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis. Neuroscience. 2013;235:1626.
doi: 10.1016/j.neuroscience.2013.01.020
Vakrakou AG, Tzanetakos D, Argyrakos T, Koutsis G, Evangelopoulos M-E, Andreadou E, et al. Recurrent fulminant tumefactive demyelination with Marburg-like features and atypical presentation: therapeutic dilemmas and review of literature. Front Neurol. 2020;11:536.
doi: 10.3389/fneur.2020.00536
Ayrignac X, Carra-Dallière C, Labauge P. Atypical inflammatory demyelinating lesions and atypical multiple sclerosis. Rev Neurol (Paris). 2018;174(6):40818.
doi: 10.1016/j.neurol.2018.03.007
Simon JH, Kleinschmidt-DeMasters BK. Variants of multiple sclerosis. Neuroimaging Clin N Am. 2008;18(4):70316.
doi: 10.1016/j.nic.2008.06.003
Frederick MC, Cameron MH. Tumefactive demyelinating lesions in multiple sclerosis and associated disorders. Curr Neurol Neurosci Rep. 2016;16(3):26.
doi: 10.1007/s11910-016-0626-9
Nozaki K, Abou-Fayssal N. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis. J Neurol Sci. 2010;296(12):1213.
Turatti M, Gajofatto A, Rossi F, Vedovello M, Benedetti MD. Long survival and clinical stability in Marburg’s variant multiple sclerosis. Neurol Sci. 2010;31(6):80711.
doi: 10.1007/s10072-010-0287-4
Avila-Ornelas J, Labat E, Alfonso G, Serrano C, Fiorito F. An extremely aggressive case of Marburg’s disease treated with high dose cyclophosphamide. A case report. Mult Scler Relat Disord. 2019;31:513.
doi: 10.1016/j.msard.2019.03.014
Gobbin F, Marangi A, Orlandi R, Richelli S, Turatti M, Calabrese M, et al. A case of acute fulminant multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord. 2017;17:911.
doi: 10.1016/j.msard.2017.06.007
Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62(2):112–8. https://doi.org/10.1136/jnnp.62.2.112.PMID:9048709;PMCID:PMC486720 .
doi: 10.1136/jnnp.62.2.112.PMID:9048709;PMCID:PMC486720 pubmed: 9048709 pmcid: 486720
Susac JO, Murtagh FR, Egan RA, Berger JR, Bakshi R, Lincoff N, et al. MRI findings in Susac’s syndrome. Neurology. 2003;61(12):17837.
doi: 10.1212/01.WNL.0000103880.29693.48
Talab R, Kundrata Z. Marburg variant multiple sclerosis: a case report. Neuro Endocrinol Lett. 2011;32(4):415–20 (PMID: 21876497).
pubmed: 21876497
Manuel A, Vasudevan MC. A case of Marburg’s variant of multiple sclerosis successfully treated with IVIg and mitoxantrone. Ann Indian Acad Neurol. 2021;24(1):92–4. https://doi.org/10.4103/aian.AIAN_117_20 .
doi: 10.4103/aian.AIAN_117_20 pubmed: 33911391 pmcid: 8061517
Jeffery DR, Lefkowitz DS, Crittenden JP. Treatment of Marburg variant multiple sclerosis with mitoxantrone. J Neuroimaging. 2004;14(1):5862.
doi: 10.1111/j.1552-6569.2004.tb00217.x

Auteurs

Nicolas Capet (N)

URRIS, Unité de Recherche Clinique Cote d'Azur-UR2CA-CRCSEP- Hôpital Pasteur 2, 30 voie romaine, 06000, Nice, France. n.capet@gmail.com.
Department of Internal Medicine, Princess Grace Hospital Center, Pasteur, Monaco. n.capet@gmail.com.
Service de Neurologie- Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 30 voie Romaine, 06000, Nice, France. n.capet@gmail.com.

Michael Levraut (M)

URRIS, Unité de Recherche Clinique Cote d'Azur-UR2CA-CRCSEP- Hôpital Pasteur 2, 30 voie romaine, 06000, Nice, France.
Service de médecine interne- Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, 151 route Saint Antoine de Ginestière, 06200, Nice, France.

Adrien Delourme (A)

Service de Neurologie- Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 30 voie Romaine, 06000, Nice, France.

Oceane Thomel-Rocchi (O)

Service de Neurologie- Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 30 voie Romaine, 06000, Nice, France.

Véronique Bourg (V)

Service de Neurologie- Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 30 voie Romaine, 06000, Nice, France.

Philippe Cabre (P)

Service de Neurologie, Université Antilles-Guyane, Hôpital Pierre Zobda Quitmann, Fort de France, Antilles Françaises, Martinique.

Fanny Vandenbos (F)

Central Laboratory of Pathology, Pasteur I University Hospital, UCA, Nice, France.

Lydiane Mondot (L)

Service de Radiologie, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 30 voie Romaine, 06000, Nice, France.

Christine Lebrun-Frenay (C)

URRIS, Unité de Recherche Clinique Cote d'Azur-UR2CA-CRCSEP- Hôpital Pasteur 2, 30 voie romaine, 06000, Nice, France.
Service de Neurologie- Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 30 voie Romaine, 06000, Nice, France.

Classifications MeSH